Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ)
- Previous Close
50.63 - Open
53.60 - Bid 50.33 x --
- Ask 50.34 x --
- Day's Range
50.25 - 51.24 - 52 Week Range
44.01 - 79.00 - Volume
1,733,200 - Avg. Volume
3,502,540 - Market Cap (intraday)
6.693B - Beta (5Y Monthly) 2.44
- PE Ratio (TTM)
24.32 - EPS (TTM)
2.07 - Earnings Date --
- Forward Dividend & Yield 2.00 (3.97%)
- Ex-Dividend Date May 8, 2024
- 1y Target Est
72.00
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.
www.kangh.comRecent News: 300841.SZ
View MorePerformance Overview: 300841.SZ
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300841.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300841.SZ
View MoreValuation Measures
Market Cap
6.69B
Enterprise Value
5.92B
Trailing P/E
24.36
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.23
Price/Book (mrq)
1.93
Enterprise Value/Revenue
4.71
Enterprise Value/EBITDA
18.50
Financial Highlights
Profitability and Income Statement
Profit Margin
21.45%
Return on Assets (ttm)
5.90%
Return on Equity (ttm)
7.64%
Revenue (ttm)
1.26B
Net Income Avi to Common (ttm)
269.89M
Diluted EPS (ttm)
2.07
Balance Sheet and Cash Flow
Total Cash (mrq)
931.95M
Total Debt/Equity (mrq)
4.65%
Levered Free Cash Flow (ttm)
210.37M